文献速递前列腺癌

前列腺特异性抗原1.8-3 ng/ml区间的前列腺癌:Göteborg-2前列腺癌筛查试验结果

Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial.
PubMed 文献 · Eur Urol · 2024-03-14

在基于人群的Göteborg-2筛查研究中,6006名男性随机入组,PSA≥1.8 ng/ml者推荐MRI,PI-RADS 3-5者行靶向穿刺。PSA 1.8-<3 ng/ml组前列腺癌检出率41%(95%CI 0.33-0.49),其中Gleason≥7占20%;PSA 3-<10 ng/ml组检出率56%(95%CI 0.46-0.66),Gleason≥7占32%。

要点

  • PSA 1.8-<3 ng/ml男性中41%(95%CI 0.33-0.49)经MRI阳性后检出前列腺癌。
  • 该组20%为Gleason≥7,临床显著癌数量不可忽视。
  • PSA 1.8-<3 ng/ml组与3-<10 ng/ml组PI-RADS 5分别为1.0%与5.3%。

核心结论

  • PSA 1.8-3 ng/ml男性中临床显著前列腺癌数量不可忽视。
  • 这些肿瘤延迟至PSA≥3 ng/ml才诊断是否影响治愈机会尚待评估。

研究设计与样本

  • 基于人群的Göteborg-2筛查研究,2015-2020年17974名男性参与PSA检测。
  • 三分之一参与者(n=6006)随机入Arm 3,PSA≥1.8 ng/ml者推荐MRI。
  • MRI阳性(PI-RADS 3-5)者对每个MRI可见病灶行4针靶向穿刺。
  • 临床显著前列腺癌定义为Gleason评分≥3+4。

主要发现

  • 6006名男性纳入,中位年龄55.9岁。
  • 670名(11%)PSA 1.8-<3 ng/ml(低PSA组),中位PSA 2.1 ng/ml;377名(6.3%)PSA 3-<10 ng/ml(高PSA组),中位PSA 3.9 ng/ml。
  • 低PSA组PI-RADS 3、4、5分别为7.8%、15%、1.0%;高PSA组分别为6.9%、17%、5.3%。
  • 低PSA组MRI阳性者中64名(41%,95%CI 0.33-0.49)检出前列腺癌,33名(21%)Gleason 6,31名(20%)Gleason≥7。
  • 高PSA组61名(56%,95%CI 0.46-0.66)检出前列腺癌,26名(24%)Gleason 6,35名(32%)Gleason≥7。

关键数值与推荐

  • 低PSA组前列腺癌检出率41%(95%CI 0.33-0.49),Gleason≥7占20%。
  • 高PSA组前列腺癌检出率56%(95%CI 0.46-0.66),Gleason≥7占32%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性包括结果仅来自单轮筛查。
  • 这些肿瘤延迟至PSA≥3 ng/ml才诊断是否影响治愈机会尚待评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Magnetic resonance imaging(MRI) and targeted biopsies reduce overdiagnosis of prostate cancer(PC). It is uncertain how this strategy performs for low PSA levels. The objective was to investigate the PI-RADS distribution, frequency and characteristics of screen-detected PC with PSA of 1.8-<3ng/ml and 3-<10ng/ml. METHODS: In the population-based Göteborg-2 screening study, 17 974 men choose to participate by having a PSA(2015-2020). One-third of the participants(n=6006) were randomized to Arm 3, men with a PSA ≥1.8ng/ml were recommended MRI. Men with positive MRI(PI-RADS3-5) had four targeted biopsies from each MRI-visible lesion. Clinically significant PC was defined as Gleason score ≥3+4. KEY FINDINGS AND LIMITATIONS: 6006 men were included. Median age was 55.9 years. 670(11%) had PSA of 1.8-<3ng/ml(low-PSA group), median PSA 2.1ng/ml, and 377(6.3%) had PSA of 3-<10ng/ml(high-PSA group), median PSA 3.9ng/ml. PI-RADS scores of 3, 4, and 5 were observed in 7.8%, 15%, and 1.0% in the low-PSA group, and in 6.9%, 17%, and 5.3% in the high-PSA group, respectively. PC was found in 64 men (41%, 95%CI 0.33-0.49) with positive MRI findings in the low-PSA group, 33(21%) had Gleason 6 and 31(20%) had Gleason ≥7. In the high-PSA group, PC was detected in 61men (56%, 95%CI 0.46-0.66), 26(24%) had Gleason 6 and 35(32%) had Gleason ≥7. Limitations include results from only a single screening round. CONCLUSIONS AND CLINICAL IMPLICATIONS: A non-negligible number of men with PSA 1.8-3ng/ml have clinically significant PC. Whether a delay in the diagnosis of these tumors until they reached PSA ≥3ng/ml would impair their chance of cure remains to be evaluated.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Möller F, Månsson M, Wallström J, et al. Prostate Cancers in the Prostate-specific Antigen Interval of 1.8-3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial. Eur Urol. 2024. PMID: 38490856. doi:10.1016/j.eururo.2024.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。